Biased ligand of the angiotensin II type 1 receptor in patients with acute heart failure: a randomized, double-blind, placebo-controlled, phase IIB, dose ranging trial (BLAST-AHF)

Currently, no acute heart failure (AHF) therapy definitively improves outcomes. Reducing morbidity and mortality from acute heart failure (AHF) remains an unmet need. TRV027 is a novel 'biased' ligand of the angiotensin II type 1 receptor (AT1R), selectively antagonizing the negative effec...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	European heart journal 2017-08, Vol.38 (30), p.2364-2373
Hauptverfasser:	Pang, Peter S, Butler, Javed, Collins, Sean P, Cotter, Gad, Davison, Beth A, Ezekowitz, Justin A, Filippatos, Gerasimos, Levy, Phillip D, Metra, Marco, Ponikowski, Piotr, Teerlink, John R, Voors, Adriaan A, Bharucha, David, Goin, Kathleen, Soergel, David G, Felker, G Michael
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Angiotensin II Type 1 Receptor Blockers - administration & dosage Clinical Research Dose-Response Relationship, Drug Double-Blind Method Female Heart Failure - drug therapy Humans Infusions, Intravenous Length of Stay Male Oligopeptides - administration & dosage Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!